Chemical complementarity between immune receptor CDR3s and IDH1 mutants correlates with increased survival for lower grade glioma
Focusing on highly specific aspects of the immune response is likely to answer a number of basic questions, and in some cases even resolve basic contradictions, in cancer immunology. For example, there are many cases, where chronic inflammation is associated with cancer development, and many other c...
Gespeichert in:
| Veröffentlicht in: | Oncogene 2020-02, Vol.39 (8), p.1773-1783 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1783 |
|---|---|
| container_issue | 8 |
| container_start_page | 1773 |
| container_title | Oncogene |
| container_volume | 39 |
| creator | Chobrutskiy, Boris I. Yeagley, Michelle Tipping, Price Zaman, Saif Diviney, Andrea Patel, Dhruv N. Falasiri, Shayan Uversky, Vladimir N. Blanck, George |
| description | Focusing on highly specific aspects of the immune response is likely to answer a number of basic questions, and in some cases even resolve basic contradictions, in cancer immunology. For example, there are many cases, where chronic inflammation is associated with cancer development, and many other cases where an immune response represents an anticancer process. In this study, using bioinformatics algorithms, we examined the chemical relationships between the amino acid sequences of the complementarity-determining region-3 (CDR3) represented by immune receptors associated with lower grade glioma and isocitrate dehydrogenase-1 (IDH1) mutants. In particular, we developed a chemical complementarity scoring approach to classify tumors based on the complementarity of CDR3s and mutant IDH1 amino acids, relying on net charge per residue and hydropathy parameters. There was a strong correlation between the increased survival in low-grade glioma (LGG) and complementarity of IDH1 mutants to the CDR3 domain of the T-cell receptor beta chain (TRB). Similar results were obtained for TRB CDR3s and NRAS mutants in melanoma. Furthermore, the clear connection between increased survival rates and immune receptor-IDH1 mutant complementarities may also, partially, explain the better LGG prognosis for patients with IDH1 mutants. |
| doi_str_mv | 10.1038/s41388-019-1101-2 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2315969067</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A618257365</galeid><sourcerecordid>A618257365</sourcerecordid><originalsourceid>FETCH-LOGICAL-c467t-68544b4a3349f007f21481924ee4599fe8fecb65d11c05722f48f96c2d123e4c3</originalsourceid><addsrcrecordid>eNp9kl9rFDEUxYNY7Lr6AXyRgC--TM3_mTyWrdpCQSjtc8hmbrYpM5k1yXTpY7-5WbZaFJU8BJLfuffc5CD0jpITSnj3KQvKu64hVDeUEtqwF2hBRasaKbV4iRZES9Joxtkxep3zHSGk1YS9QsectoK0nVigx9UtjMHZAbtp3A4wQiw2hfKA11B2ABGHcZwj4AQOtmVKeHV2xTO2sccXZ-cUj3OxseQqTwkGWyDjXSi3OESXwGbocZ7TfbivHXxVD9MOEt4k2wPeDGEa7Rt05O2Q4e3TvkQ3Xz5fr86by29fL1anl40Tqi2N6qQQa2E5F9rXQTyjoqOaCQAhtfbQeXBrJXtKHZEtY150XivHeso4CMeX6OOh7jZN32fIxYwhOxgGG2Gas2GcSq00UW1FP_yB3k1zitWdYfV5W0WpIv-luNS85ULoZ2pjBzAh-qkk6_atzamiHZMtV7JSJ3-h6ur3vzNF8KGe_yagB4FLU84JvNmmMNr0YCgx-3CYQzhMDYfZh6N6WqL3T4bn9Qj9L8XPNFSAHYBcr-IG0vNE_676A6lPwjc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2359373449</pqid></control><display><type>article</type><title>Chemical complementarity between immune receptor CDR3s and IDH1 mutants correlates with increased survival for lower grade glioma</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Chobrutskiy, Boris I. ; Yeagley, Michelle ; Tipping, Price ; Zaman, Saif ; Diviney, Andrea ; Patel, Dhruv N. ; Falasiri, Shayan ; Uversky, Vladimir N. ; Blanck, George</creator><creatorcontrib>Chobrutskiy, Boris I. ; Yeagley, Michelle ; Tipping, Price ; Zaman, Saif ; Diviney, Andrea ; Patel, Dhruv N. ; Falasiri, Shayan ; Uversky, Vladimir N. ; Blanck, George</creatorcontrib><description>Focusing on highly specific aspects of the immune response is likely to answer a number of basic questions, and in some cases even resolve basic contradictions, in cancer immunology. For example, there are many cases, where chronic inflammation is associated with cancer development, and many other cases where an immune response represents an anticancer process. In this study, using bioinformatics algorithms, we examined the chemical relationships between the amino acid sequences of the complementarity-determining region-3 (CDR3) represented by immune receptors associated with lower grade glioma and isocitrate dehydrogenase-1 (IDH1) mutants. In particular, we developed a chemical complementarity scoring approach to classify tumors based on the complementarity of CDR3s and mutant IDH1 amino acids, relying on net charge per residue and hydropathy parameters. There was a strong correlation between the increased survival in low-grade glioma (LGG) and complementarity of IDH1 mutants to the CDR3 domain of the T-cell receptor beta chain (TRB). Similar results were obtained for TRB CDR3s and NRAS mutants in melanoma. Furthermore, the clear connection between increased survival rates and immune receptor-IDH1 mutant complementarities may also, partially, explain the better LGG prognosis for patients with IDH1 mutants.</description><identifier>ISSN: 0950-9232</identifier><identifier>EISSN: 1476-5594</identifier><identifier>DOI: 10.1038/s41388-019-1101-2</identifier><identifier>PMID: 31740784</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>38/1 ; 38/23 ; 45/70 ; 631/67/327 ; 692/53/2422 ; Apoptosis ; Bioinformatics ; Brain tumors ; Care and treatment ; Cell Biology ; Cell receptors ; Complementarity Determining Regions - genetics ; Complementarity Determining Regions - metabolism ; Complementarity-determining region 3 ; Complementarity-determining regions ; Development and progression ; Gene Expression Regulation, Neoplastic ; Gene mutations ; Genetic aspects ; Glioma ; Glioma - genetics ; Glioma - pathology ; Gliomas ; Health aspects ; Human Genetics ; Humans ; Immune response ; Internal Medicine ; Isocitrate dehydrogenase ; Isocitrate Dehydrogenase - genetics ; Isocitrate Dehydrogenase - metabolism ; Kaplan-Meier Estimate ; Lymphocytes T ; Medical prognosis ; Medicine ; Medicine & Public Health ; Melanoma ; Mutants ; Mutation ; Neoplasm Grading ; Oncology ; T cell receptors</subject><ispartof>Oncogene, 2020-02, Vol.39 (8), p.1773-1783</ispartof><rights>The Author(s), under exclusive licence to Springer Nature Limited 2019</rights><rights>COPYRIGHT 2020 Nature Publishing Group</rights><rights>2019© The Author(s), under exclusive licence to Springer Nature Limited 2019</rights><rights>The Author(s), under exclusive licence to Springer Nature Limited 2019.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c467t-68544b4a3349f007f21481924ee4599fe8fecb65d11c05722f48f96c2d123e4c3</citedby><cites>FETCH-LOGICAL-c467t-68544b4a3349f007f21481924ee4599fe8fecb65d11c05722f48f96c2d123e4c3</cites><orcidid>0000-0003-1664-0996 ; 0000-0002-4037-5857</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31740784$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chobrutskiy, Boris I.</creatorcontrib><creatorcontrib>Yeagley, Michelle</creatorcontrib><creatorcontrib>Tipping, Price</creatorcontrib><creatorcontrib>Zaman, Saif</creatorcontrib><creatorcontrib>Diviney, Andrea</creatorcontrib><creatorcontrib>Patel, Dhruv N.</creatorcontrib><creatorcontrib>Falasiri, Shayan</creatorcontrib><creatorcontrib>Uversky, Vladimir N.</creatorcontrib><creatorcontrib>Blanck, George</creatorcontrib><title>Chemical complementarity between immune receptor CDR3s and IDH1 mutants correlates with increased survival for lower grade glioma</title><title>Oncogene</title><addtitle>Oncogene</addtitle><addtitle>Oncogene</addtitle><description>Focusing on highly specific aspects of the immune response is likely to answer a number of basic questions, and in some cases even resolve basic contradictions, in cancer immunology. For example, there are many cases, where chronic inflammation is associated with cancer development, and many other cases where an immune response represents an anticancer process. In this study, using bioinformatics algorithms, we examined the chemical relationships between the amino acid sequences of the complementarity-determining region-3 (CDR3) represented by immune receptors associated with lower grade glioma and isocitrate dehydrogenase-1 (IDH1) mutants. In particular, we developed a chemical complementarity scoring approach to classify tumors based on the complementarity of CDR3s and mutant IDH1 amino acids, relying on net charge per residue and hydropathy parameters. There was a strong correlation between the increased survival in low-grade glioma (LGG) and complementarity of IDH1 mutants to the CDR3 domain of the T-cell receptor beta chain (TRB). Similar results were obtained for TRB CDR3s and NRAS mutants in melanoma. Furthermore, the clear connection between increased survival rates and immune receptor-IDH1 mutant complementarities may also, partially, explain the better LGG prognosis for patients with IDH1 mutants.</description><subject>38/1</subject><subject>38/23</subject><subject>45/70</subject><subject>631/67/327</subject><subject>692/53/2422</subject><subject>Apoptosis</subject><subject>Bioinformatics</subject><subject>Brain tumors</subject><subject>Care and treatment</subject><subject>Cell Biology</subject><subject>Cell receptors</subject><subject>Complementarity Determining Regions - genetics</subject><subject>Complementarity Determining Regions - metabolism</subject><subject>Complementarity-determining region 3</subject><subject>Complementarity-determining regions</subject><subject>Development and progression</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Gene mutations</subject><subject>Genetic aspects</subject><subject>Glioma</subject><subject>Glioma - genetics</subject><subject>Glioma - pathology</subject><subject>Gliomas</subject><subject>Health aspects</subject><subject>Human Genetics</subject><subject>Humans</subject><subject>Immune response</subject><subject>Internal Medicine</subject><subject>Isocitrate dehydrogenase</subject><subject>Isocitrate Dehydrogenase - genetics</subject><subject>Isocitrate Dehydrogenase - metabolism</subject><subject>Kaplan-Meier Estimate</subject><subject>Lymphocytes T</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Melanoma</subject><subject>Mutants</subject><subject>Mutation</subject><subject>Neoplasm Grading</subject><subject>Oncology</subject><subject>T cell receptors</subject><issn>0950-9232</issn><issn>1476-5594</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kl9rFDEUxYNY7Lr6AXyRgC--TM3_mTyWrdpCQSjtc8hmbrYpM5k1yXTpY7-5WbZaFJU8BJLfuffc5CD0jpITSnj3KQvKu64hVDeUEtqwF2hBRasaKbV4iRZES9Joxtkxep3zHSGk1YS9QsectoK0nVigx9UtjMHZAbtp3A4wQiw2hfKA11B2ABGHcZwj4AQOtmVKeHV2xTO2sccXZ-cUj3OxseQqTwkGWyDjXSi3OESXwGbocZ7TfbivHXxVD9MOEt4k2wPeDGEa7Rt05O2Q4e3TvkQ3Xz5fr86by29fL1anl40Tqi2N6qQQa2E5F9rXQTyjoqOaCQAhtfbQeXBrJXtKHZEtY150XivHeso4CMeX6OOh7jZN32fIxYwhOxgGG2Gas2GcSq00UW1FP_yB3k1zitWdYfV5W0WpIv-luNS85ULoZ2pjBzAh-qkk6_atzamiHZMtV7JSJ3-h6ur3vzNF8KGe_yagB4FLU84JvNmmMNr0YCgx-3CYQzhMDYfZh6N6WqL3T4bn9Qj9L8XPNFSAHYBcr-IG0vNE_676A6lPwjc</recordid><startdate>20200201</startdate><enddate>20200201</enddate><creator>Chobrutskiy, Boris I.</creator><creator>Yeagley, Michelle</creator><creator>Tipping, Price</creator><creator>Zaman, Saif</creator><creator>Diviney, Andrea</creator><creator>Patel, Dhruv N.</creator><creator>Falasiri, Shayan</creator><creator>Uversky, Vladimir N.</creator><creator>Blanck, George</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1664-0996</orcidid><orcidid>https://orcid.org/0000-0002-4037-5857</orcidid></search><sort><creationdate>20200201</creationdate><title>Chemical complementarity between immune receptor CDR3s and IDH1 mutants correlates with increased survival for lower grade glioma</title><author>Chobrutskiy, Boris I. ; Yeagley, Michelle ; Tipping, Price ; Zaman, Saif ; Diviney, Andrea ; Patel, Dhruv N. ; Falasiri, Shayan ; Uversky, Vladimir N. ; Blanck, George</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c467t-68544b4a3349f007f21481924ee4599fe8fecb65d11c05722f48f96c2d123e4c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>38/1</topic><topic>38/23</topic><topic>45/70</topic><topic>631/67/327</topic><topic>692/53/2422</topic><topic>Apoptosis</topic><topic>Bioinformatics</topic><topic>Brain tumors</topic><topic>Care and treatment</topic><topic>Cell Biology</topic><topic>Cell receptors</topic><topic>Complementarity Determining Regions - genetics</topic><topic>Complementarity Determining Regions - metabolism</topic><topic>Complementarity-determining region 3</topic><topic>Complementarity-determining regions</topic><topic>Development and progression</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Gene mutations</topic><topic>Genetic aspects</topic><topic>Glioma</topic><topic>Glioma - genetics</topic><topic>Glioma - pathology</topic><topic>Gliomas</topic><topic>Health aspects</topic><topic>Human Genetics</topic><topic>Humans</topic><topic>Immune response</topic><topic>Internal Medicine</topic><topic>Isocitrate dehydrogenase</topic><topic>Isocitrate Dehydrogenase - genetics</topic><topic>Isocitrate Dehydrogenase - metabolism</topic><topic>Kaplan-Meier Estimate</topic><topic>Lymphocytes T</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Melanoma</topic><topic>Mutants</topic><topic>Mutation</topic><topic>Neoplasm Grading</topic><topic>Oncology</topic><topic>T cell receptors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chobrutskiy, Boris I.</creatorcontrib><creatorcontrib>Yeagley, Michelle</creatorcontrib><creatorcontrib>Tipping, Price</creatorcontrib><creatorcontrib>Zaman, Saif</creatorcontrib><creatorcontrib>Diviney, Andrea</creatorcontrib><creatorcontrib>Patel, Dhruv N.</creatorcontrib><creatorcontrib>Falasiri, Shayan</creatorcontrib><creatorcontrib>Uversky, Vladimir N.</creatorcontrib><creatorcontrib>Blanck, George</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Oncogene</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chobrutskiy, Boris I.</au><au>Yeagley, Michelle</au><au>Tipping, Price</au><au>Zaman, Saif</au><au>Diviney, Andrea</au><au>Patel, Dhruv N.</au><au>Falasiri, Shayan</au><au>Uversky, Vladimir N.</au><au>Blanck, George</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chemical complementarity between immune receptor CDR3s and IDH1 mutants correlates with increased survival for lower grade glioma</atitle><jtitle>Oncogene</jtitle><stitle>Oncogene</stitle><addtitle>Oncogene</addtitle><date>2020-02-01</date><risdate>2020</risdate><volume>39</volume><issue>8</issue><spage>1773</spage><epage>1783</epage><pages>1773-1783</pages><issn>0950-9232</issn><eissn>1476-5594</eissn><abstract>Focusing on highly specific aspects of the immune response is likely to answer a number of basic questions, and in some cases even resolve basic contradictions, in cancer immunology. For example, there are many cases, where chronic inflammation is associated with cancer development, and many other cases where an immune response represents an anticancer process. In this study, using bioinformatics algorithms, we examined the chemical relationships between the amino acid sequences of the complementarity-determining region-3 (CDR3) represented by immune receptors associated with lower grade glioma and isocitrate dehydrogenase-1 (IDH1) mutants. In particular, we developed a chemical complementarity scoring approach to classify tumors based on the complementarity of CDR3s and mutant IDH1 amino acids, relying on net charge per residue and hydropathy parameters. There was a strong correlation between the increased survival in low-grade glioma (LGG) and complementarity of IDH1 mutants to the CDR3 domain of the T-cell receptor beta chain (TRB). Similar results were obtained for TRB CDR3s and NRAS mutants in melanoma. Furthermore, the clear connection between increased survival rates and immune receptor-IDH1 mutant complementarities may also, partially, explain the better LGG prognosis for patients with IDH1 mutants.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>31740784</pmid><doi>10.1038/s41388-019-1101-2</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0003-1664-0996</orcidid><orcidid>https://orcid.org/0000-0002-4037-5857</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0950-9232 |
| ispartof | Oncogene, 2020-02, Vol.39 (8), p.1773-1783 |
| issn | 0950-9232 1476-5594 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2315969067 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | 38/1 38/23 45/70 631/67/327 692/53/2422 Apoptosis Bioinformatics Brain tumors Care and treatment Cell Biology Cell receptors Complementarity Determining Regions - genetics Complementarity Determining Regions - metabolism Complementarity-determining region 3 Complementarity-determining regions Development and progression Gene Expression Regulation, Neoplastic Gene mutations Genetic aspects Glioma Glioma - genetics Glioma - pathology Gliomas Health aspects Human Genetics Humans Immune response Internal Medicine Isocitrate dehydrogenase Isocitrate Dehydrogenase - genetics Isocitrate Dehydrogenase - metabolism Kaplan-Meier Estimate Lymphocytes T Medical prognosis Medicine Medicine & Public Health Melanoma Mutants Mutation Neoplasm Grading Oncology T cell receptors |
| title | Chemical complementarity between immune receptor CDR3s and IDH1 mutants correlates with increased survival for lower grade glioma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T08%3A57%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chemical%20complementarity%20between%20immune%20receptor%20CDR3s%20and%20IDH1%20mutants%20correlates%20with%20increased%20survival%20for%20lower%20grade%20glioma&rft.jtitle=Oncogene&rft.au=Chobrutskiy,%20Boris%20I.&rft.date=2020-02-01&rft.volume=39&rft.issue=8&rft.spage=1773&rft.epage=1783&rft.pages=1773-1783&rft.issn=0950-9232&rft.eissn=1476-5594&rft_id=info:doi/10.1038/s41388-019-1101-2&rft_dat=%3Cgale_proqu%3EA618257365%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2359373449&rft_id=info:pmid/31740784&rft_galeid=A618257365&rfr_iscdi=true |